DK2989893T3 - Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde - Google Patents

Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde Download PDF

Info

Publication number
DK2989893T3
DK2989893T3 DK15186515.1T DK15186515T DK2989893T3 DK 2989893 T3 DK2989893 T3 DK 2989893T3 DK 15186515 T DK15186515 T DK 15186515T DK 2989893 T3 DK2989893 T3 DK 2989893T3
Authority
DK
Denmark
Prior art keywords
light chain
chain antibodies
human animals
common light
animals expressing
Prior art date
Application number
DK15186515.1T
Other languages
Danish (da)
English (en)
Inventor
John Mcwhirter
Sean Stevens
Samuel Davis
David R Buckler
Andrew J Murphy
Lynn Macdonald
Karolina A Hosiawa
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46000410&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2989893(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Application granted granted Critical
Publication of DK2989893T3 publication Critical patent/DK2989893T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/10—Cells modified by introduction of foreign genetic material
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/15—Animals comprising multiple alterations of the genome, by transgenesis or homologous recombination, e.g. obtained by cross-breeding
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/20—Pseudochromosomes, minichrosomosomes
    • C12N2800/204—Pseudochromosomes, minichrosomosomes of bacterial origin, e.g. BAC

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Environmental Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cell Biology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK15186515.1T 2011-04-25 2012-04-24 Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde DK2989893T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13/093,156 US20120021409A1 (en) 2010-02-08 2011-04-25 Common Light Chain Mouse
EP12717033.0A EP2701499B2 (en) 2011-04-25 2012-04-24 Non-human animals expressing antibodies having a common light chain

Publications (1)

Publication Number Publication Date
DK2989893T3 true DK2989893T3 (da) 2019-09-09

Family

ID=46000410

Family Applications (2)

Application Number Title Priority Date Filing Date
DK15186515.1T DK2989893T3 (da) 2011-04-25 2012-04-24 Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
DK12717033.0T DK2701499T4 (da) 2011-04-25 2012-04-24 Ikke-humane dyr, der udtrykker antistoffer med en fælles letkæde

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK12717033.0T DK2701499T4 (da) 2011-04-25 2012-04-24 Ikke-humane dyr, der udtrykker antistoffer med en fælles letkæde

Country Status (25)

Country Link
US (2) US20120021409A1 (sr)
EP (2) EP2989893B1 (sr)
JP (2) JP6393613B2 (sr)
KR (1) KR101995753B1 (sr)
CN (2) CN103596424B (sr)
AU (3) AU2012249953B2 (sr)
BR (1) BR112013027420A2 (sr)
CA (1) CA2846806A1 (sr)
CY (2) CY1117606T1 (sr)
DK (2) DK2989893T3 (sr)
ES (2) ES2743681T3 (sr)
HK (2) HK1193718A1 (sr)
HR (2) HRP20160484T4 (sr)
HU (2) HUE027949T2 (sr)
IL (1) IL228929A0 (sr)
LT (1) LT2989893T (sr)
MX (1) MX353609B (sr)
PL (2) PL2989893T3 (sr)
PT (1) PT2989893T (sr)
RS (2) RS54831B2 (sr)
RU (2) RU2017108634A (sr)
SG (1) SG194466A1 (sr)
SI (2) SI2989893T1 (sr)
SM (1) SMT201600133B (sr)
WO (1) WO2012148873A2 (sr)

Families Citing this family (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT2314629E (pt) 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
US20100069614A1 (en) 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
DK3028564T5 (da) 2009-07-08 2024-04-29 Kymab Ltd Dyremodeller og terapeutiske molekyler
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
US20120204278A1 (en) 2009-07-08 2012-08-09 Kymab Limited Animal models and therapeutic molecules
US9796788B2 (en) 2010-02-08 2017-10-24 Regeneron Pharmaceuticals, Inc. Mice expressing a limited immunoglobulin light chain repertoire
US20130045492A1 (en) 2010-02-08 2013-02-21 Regeneron Pharmaceuticals, Inc. Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain
PT2505654T (pt) 2010-02-08 2016-11-18 Regeneron Pharma Rato de cadeia leve comum
JP6146913B2 (ja) 2010-08-02 2017-06-14 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｖｌドメインを含む結合タンパク質を作製するマウス
CN103429737B (zh) 2010-11-30 2020-07-14 中外制药株式会社 细胞毒诱导治疗剂
ES2748832T5 (es) 2011-02-25 2023-06-08 Regeneron Pharma Ratones ADAM6
WO2012116926A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Antigen binding proteins
AR085403A1 (es) 2011-02-28 2013-09-25 Hoffmann La Roche Proteinas monovalentes que se unen a antigenos
EP3865581A1 (en) 2011-08-05 2021-08-18 Regeneron Pharmaceuticals, Inc. Humanized universal light chain mice
DK2757875T3 (en) 2011-09-19 2018-01-08 Kymab Ltd MANIPULATION OF IMMUNOGLOBULIN GENE DIVERSITY AND MULTI-ANTIBODY THERAPEUTICS
CA2791109C (en) 2011-09-26 2021-02-16 Merus B.V. Generation of binding molecules
EP2761008A1 (en) 2011-09-26 2014-08-06 Kymab Limited Chimaeric surrogate light chains (slc) comprising human vpreb
EP2627773B1 (en) 2011-10-17 2017-06-14 Regeneron Pharmaceuticals, Inc. Restricted immunoglobulin heavy chain mice
US9253965B2 (en) 2012-03-28 2016-02-09 Kymab Limited Animal models and therapeutic molecules
KR102081657B1 (ko) 2011-12-20 2020-02-26 리제너론 파마슈티칼스 인코포레이티드 인간화 경쇄 마우스
LT2883449T (lt) 2012-03-16 2018-05-10 Regeneron Pharmaceuticals, Inc. Histidinu modifikuoti lengvosios grandinės antikūnai ir juos gaminantys genetiškai modifikuoti graužikai
US20140013456A1 (en) 2012-03-16 2014-01-09 Regeneron Pharmaceuticals, Inc. Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same
NZ730271A (en) 2012-03-16 2022-09-30 Regeneron Pharma Non-human animals expressing ph-sensitive immunoglobulin sequences
WO2013138681A1 (en) 2012-03-16 2013-09-19 Regeneron Pharmaceuticals, Inc. Mice that produce antigen-binding proteins with ph-dependent binding characteristics
GB2502127A (en) 2012-05-17 2013-11-20 Kymab Ltd Multivalent antibodies and in vivo methods for their production
US10251377B2 (en) 2012-03-28 2019-04-09 Kymab Limited Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies
NZ772318A (en) 2012-04-20 2023-06-30 Merus Nv Methods and means for the production of ig-like molecules
SG11201407789RA (en) * 2012-06-12 2014-12-30 Regeneron Pharma Humanized non-human animals with restricted immunoglobulin heavy chain loci
WO2014022540A1 (en) 2012-08-02 2014-02-06 Regeneron Pharmaceuticals, Inc. Multivalent antigen-binding proteins
AU2014218915B2 (en) * 2013-02-20 2017-01-19 Regeneron Pharmaceuticals, Inc. Non-human animals with modified immunoglobulin heavy chain sequences
NL2012424C2 (en) * 2013-03-13 2014-12-08 Regeneron Pharma Common light chain mouse.
DK2967013T3 (en) * 2013-03-13 2019-03-11 Regeneron Pharma Mice expressing a restricted immunoglobulin light chain repertoire
US9788534B2 (en) 2013-03-18 2017-10-17 Kymab Limited Animal models and therapeutic molecules
KR102049990B1 (ko) 2013-03-28 2019-12-03 삼성전자주식회사 c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질
US9783618B2 (en) 2013-05-01 2017-10-10 Kymab Limited Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics
US9783593B2 (en) 2013-05-02 2017-10-10 Kymab Limited Antibodies, variable domains and chains tailored for human use
US11707056B2 (en) 2013-05-02 2023-07-25 Kymab Limited Animals, repertoires and methods
RS59003B1 (sr) * 2013-09-18 2019-08-30 Regeneron Pharma Antitela sa histidinom modifikovanim lakim lancem i genetski modifikovane nehumane životinje koje ih generišu
EP3794941A1 (en) 2013-10-01 2021-03-24 Kymab Limited Animal models and therapeutic molecules
CA2922912A1 (en) 2013-10-11 2015-04-16 F. Hoffmann-La Roche Ag Multispecific domain exchanged common variable light chain antibodies
CA2941514A1 (en) 2014-03-21 2015-09-24 Regeneron Pharmaceuticals, Inc. Vl antigen binding proteins exhibiting distinct binding characteristics
EP3119194B1 (en) 2014-03-21 2021-04-28 Regeneron Pharmaceuticals, Inc. Non-human animals that make single domain binding proteins
SI3151921T1 (sl) 2014-06-06 2019-12-31 Bristol-Myers Squibb Company Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
CA2963470A1 (en) 2014-10-03 2016-04-07 Massachusetts Institute Of Technology Antibodies that bind ebola glycoprotein and uses thereof
HUE050596T2 (hu) 2014-11-21 2020-12-28 Bristol Myers Squibb Co Antitestek CD73 ellen és azok felhasználásai
JP6738348B2 (ja) 2014-12-19 2020-08-12 リジェネサンス ベスローテン フェンノートシャップ ヒトｃ６に結合する抗体およびその使用
AU2015369683C1 (en) 2014-12-23 2024-06-20 Bristol-Myers Squibb Company Antibodies to TIGIT
US11111314B2 (en) 2015-03-19 2021-09-07 Regeneron Pharmaceuticals, Inc. Non-human animals that select for light chain variable regions that bind antigen
HRP20230060T1 (hr) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antitijela protiv ox40 i njihova primjena
BR112017028353A2 (pt) 2015-06-29 2018-09-04 The Rockfeller University anticorpos para cd40 com atividade agonista melhorada
TW201713690A (zh) * 2015-08-07 2017-04-16 再生元醫藥公司 抗ａｎｇｐｔｌ８抗體及其用途
US11033009B2 (en) * 2015-08-27 2021-06-15 Crystal Bioscience Inc. Transgenic chicken for production of antibodies having a common light chain
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
KR20230006929A (ko) 2016-01-13 2023-01-11 리제너론 파마슈티칼스 인코포레이티드 조작된 중쇄 다양성 영역을 갖는 설치류
EP3423489A1 (en) 2016-03-04 2019-01-09 The Rockefeller University Antibodies to cd40 with enhanced agonist activity
US20190284293A1 (en) 2016-03-04 2019-09-19 Bristol-Myers Squibb Company Combination therapy with anti-cd73 antibodies
TW202214700A (zh) 2016-03-14 2022-04-16 日商中外製藥股份有限公司 用於癌之治療的細胞傷害誘導治療劑
KR102417687B1 (ko) 2016-05-09 2022-07-07 브리스톨-마이어스 스큅 컴퍼니 Tl1a 항체 및 그의 용도
RU2021106817A (ru) 2016-05-20 2021-04-06 Регенерон Фармасьютикалс, Инк. Способы преодоления иммунологической толерантности с использованием множества направляющих рнк
CN116458475A (zh) * 2016-06-03 2023-07-21 瑞泽恩制药公司 表达外源末端脱氧核苷酸转移酶的非人动物
TWI780057B (zh) 2016-07-14 2022-10-11 美商必治妥美雅史谷比公司 針對tim3之抗體及其用途
WO2018044970A1 (en) 2016-08-31 2018-03-08 University Of Rochester Human monoclonal antibodies to human endogenous retrovirus k envelope (herv-k) and uses thereof
AU2017343778A1 (en) 2016-10-13 2019-05-02 Massachusetts Institute Of Technology Antibodies that bind Zika virus envelope protein and uses thereof
SG11201906947SA (en) 2017-02-17 2019-08-27 Bristol Myers Squibb Co Antibodies to alpha-synuclein and uses thereof
TWI788340B (zh) 2017-04-07 2023-01-01 美商必治妥美雅史谷比公司 抗icos促效劑抗體及其用途
GB201710984D0 (en) * 2017-07-07 2017-08-23 Kymab Ltd Cells, vertebrates, populations & methods
US11977081B2 (en) 2017-12-18 2024-05-07 Regeneron Pharmaceuticals, Inc. ANGPTL8 assay and uses thereof
KR20200108870A (ko) 2018-01-12 2020-09-21 브리스톨-마이어스 스큅 컴퍼니 Tim3에 대한 항체 및 그의 용도
MX2020009861A (es) 2018-03-23 2020-10-08 Bristol Myers Squibb Co Anticuerpos contra el complejo principal de histocompatibilidad relacionado con las cadenas a y b clase i (mica) y/o (micb) y sus usos.
CN112040769B (zh) 2018-03-24 2023-05-16 瑞泽恩制药公司 用于产生针对肽-mhc复合物的治疗抗体的经过基因修饰的非人动物、制造方法和用途
US20190380316A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
WO2020102501A1 (en) 2018-11-16 2020-05-22 Bristol-Myers Squibb Company Anti-nkg2a antibodies and uses thereof
PE20212305A1 (es) 2019-01-22 2021-12-10 Bristol Myers Squibb Co Anticuerpos contra subunidad alfa il-7r y usos de estos
JP2022520819A (ja) 2019-02-22 2022-04-01 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 遺伝子改変ナトリウムチャネルを有する齧歯類およびその使用方法
JP2022543669A (ja) 2019-08-08 2022-10-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 新規抗原結合分子フォーマット
WO2021113297A1 (en) 2019-12-02 2021-06-10 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
KR20210095781A (ko) 2020-01-24 2021-08-03 주식회사 에이프릴바이오 항원결합 단편 및 생리활성 이펙터 모이어티로 구성된 융합 컨스트럭트를 포함하는 다중결합항체 및 이를 포함하는 약학조성물
WO2021231732A1 (en) 2020-05-15 2021-11-18 Bristol-Myers Squibb Company Antibodies to garp
US20220090060A1 (en) 2020-09-11 2022-03-24 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
KR20230147048A (ko) 2020-12-16 2023-10-20 리제너론 파마슈티칼스 인코포레이티드 인간화 Fc 알파 수용체를 발현하는 마우스
US20220195014A1 (en) 2020-12-23 2022-06-23 Regeneron Pharmaceuticals, Inc. Nucleic acids encoding anchor modified antibodies and uses thereof
MX2023007583A (es) 2020-12-23 2023-07-07 Regeneron Pharma Metodos para obtener anticuerpos que se unen a proteinas transmembranarias y celulas que los producen.

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
IL109168A0 (en) * 1993-04-01 1994-06-24 Univ Columbia A retroviral vector capable of transducing the aldehyde dehydrogenase-1 gene and making cells resistant to the chemotherapeutic agent cyclophosphamide and its derivatives and analogs
US7227002B1 (en) * 1997-04-14 2007-06-05 Micromet Ag Human antibodies that bind human 17-A1/EpCAM tumor antigen
DE69830901T2 (de) * 1997-05-02 2006-05-24 Genentech Inc., San Francisco ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP2298809A3 (en) * 2001-07-12 2012-02-15 FOOTE, Jefferson Super humanized antibodies
DE50115587D1 (de) * 2001-10-01 2010-09-16 Deutsches Krebsforsch Verfahren zur Herstellung von Protein-Bibliotheken und zur Selektion von Proteinen daraus
WO2003047336A2 (en) * 2001-11-30 2003-06-12 Abgenix, Inc. TRANSGENIC ANIMALS BEARING HUMAN Igμ LIGHT CHAIN GENES
WO2003061363A2 (en) * 2002-01-17 2003-07-31 Albert Einstein College Of Medicine Of Yeshiva University Mutations caused by activation-induced cytidine deaminase
CN101824090B (zh) * 2002-06-14 2013-01-02 免疫医疗公司 人源化单克隆抗体hPAM4
PT2314629E (pt) * 2002-07-18 2014-01-22 Merus B V Produção recombinante de misturas de anticorpos
US20100069614A1 (en) * 2008-06-27 2010-03-18 Merus B.V. Antibody producing non-human mammals
ES2408582T3 (es) 2003-05-30 2013-06-21 Merus B.V. Biblioteca de Fab para la preparación de una mezcla de anticuerpos
CN1560081A (zh) * 2004-02-17 2005-01-05 大连帝恩生物工程有限公司 用能产生人IgGl重链－κ轻链小鼠作为制备人源化单克隆抗体和应用
PT1802193E (pt) 2004-10-19 2014-06-23 Regeneron Pharma Método para gerar um murganho homozigótico para uma modificação genética
JP2009518320A (ja) * 2005-12-05 2009-05-07 シュムフォウエン アクティーゼルスカブ 抗オルトポックスウイルス組換えポリクローナル抗体
CN102585002A (zh) 2006-06-02 2012-07-18 瑞泽恩制药公司 人il-6受体的高亲和力抗体
US7608693B2 (en) * 2006-10-02 2009-10-27 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human IL-4 receptor
AU2008224950B2 (en) * 2007-03-13 2013-10-03 National Jewish Medical And Research Center Methods for generation of antibodies
ITMI20071522A1 (it) * 2007-07-27 2009-01-28 Areta Internat S R L Vaccino idiotipico
SI3456190T1 (sl) * 2008-06-27 2022-06-30 Merus N.V. Transgena mišja živali, ki proizvaja protitelesa
CA2742969A1 (en) * 2008-11-07 2010-05-14 Fabrus Llc Anti-dll4 antibodies and uses thereof
MX2011012696A (es) * 2009-05-29 2012-03-29 Morphosys Ag Una coleccion y metodos para su uso.
EP2445936A1 (en) * 2009-06-26 2012-05-02 Regeneron Pharmaceuticals, Inc. Readily isolated bispecific antibodies with native immunoglobulin format
PT2505654T (pt) * 2010-02-08 2016-11-18 Regeneron Pharma Rato de cadeia leve comum
WO2013184761A1 (en) 2012-06-05 2013-12-12 Regeneron Pharmaceuticals, Inc. Methods for making fully human bispecific antibodies using a common light chain

Also Published As

Publication number Publication date
EP2701499B8 (en) 2016-03-16
EP2989893A1 (en) 2016-03-02
AU2018236913A1 (en) 2018-10-25
HRP20160484T4 (hr) 2021-12-10
EP2989893B1 (en) 2019-06-19
PL2989893T3 (pl) 2019-12-31
LT2989893T (lt) 2019-09-10
SI2701499T1 (sl) 2016-10-28
SI2989893T1 (sl) 2019-10-30
BR112013027420A2 (pt) 2016-08-09
CY1117606T1 (el) 2017-04-26
ES2573828T3 (es) 2016-06-10
PT2989893T (pt) 2019-09-23
JP6393613B2 (ja) 2018-09-19
PL2701499T3 (pl) 2017-03-31
PL2701499T5 (pl) 2021-12-13
EP2701499A2 (en) 2014-03-05
RU2614859C2 (ru) 2017-03-29
WO2012148873A3 (en) 2013-02-07
AU2016202609B2 (en) 2018-07-12
HRP20191680T1 (hr) 2019-12-13
US20120021409A1 (en) 2012-01-26
SI2701499T2 (sl) 2022-01-31
SG194466A1 (en) 2013-12-30
EP2701499B2 (en) 2021-08-18
AU2012249953B2 (en) 2016-01-28
AU2016202609A2 (en) 2017-02-02
WO2012148873A4 (en) 2013-03-14
MX2013012500A (es) 2014-02-03
HUE045401T2 (hu) 2019-12-30
NZ617158A (en) 2016-04-29
JP6522557B2 (ja) 2019-05-29
HK1193718A1 (zh) 2014-10-03
SMT201600133B (it) 2016-07-01
ES2573828T5 (es) 2022-02-28
JP2014516518A (ja) 2014-07-17
US20150313193A1 (en) 2015-11-05
EP2701499B9 (en) 2016-05-18
RS59331B1 (sr) 2019-10-31
RS54831B2 (sr) 2021-12-31
AU2012249953A1 (en) 2013-05-02
JP2016178948A (ja) 2016-10-13
CY1122036T1 (el) 2020-10-14
HRP20160484T1 (hr) 2016-06-03
AU2016202609A1 (en) 2016-05-19
ES2743681T3 (es) 2020-02-20
CA2846806A1 (en) 2012-11-01
RU2013152221A (ru) 2015-05-27
WO2012148873A2 (en) 2012-11-01
EP2701499B1 (en) 2016-02-10
IL228929A0 (en) 2013-12-31
RU2017108634A (ru) 2019-01-22
HK1220866A1 (zh) 2017-05-19
RS54831B1 (sr) 2016-10-31
MX353609B (es) 2018-01-18
DK2701499T3 (en) 2016-05-23
CN103596424A (zh) 2014-02-19
KR20140024909A (ko) 2014-03-03
DK2701499T4 (da) 2021-11-15
HUE027949T2 (en) 2016-11-28
CN105884887A (zh) 2016-08-24
CN103596424B (zh) 2016-01-20
KR101995753B1 (ko) 2019-07-03

Similar Documents

Publication Publication Date Title
DK2989893T3 (da) Ikke-humane dyr, der udtrykker antistoffer med fælles letkæde
CO7020871A2 (es) Anticuerpos anti-il-36r
DK3572517T3 (da) Humaniserede, universelle letkæde-mus
CO6811812A2 (es) Anticuerpo anti-b7-h3
DK2858487T3 (da) Humaniserede ikke-humane dyr med begrænsede immunoglobulin-tungkæde-loci
CR20140127A (es) Anticuerpo anti-abtcr
BR112013023808A2 (pt) montagem de ligação
DK3046412T3 (da) Histidin-manipulerede letkæde-antistoffer og genetisk modificerede ikke-humane dyr til generering heraf
DK2931748T3 (da) Bmp-6-antistoffer
ITMI20120024A1 (it) Bilanciere
HK1205145A1 (en) Improved antibody light chains
CO6841994A2 (es) Anticuerpos
FR2978994B1 (fr) .
DK3074661T3 (da) Kædestrammer
SMT201400073B (it) Carrucola
DE102010023409A8 (de) Kettenführung
DE112013005931A5 (de) Laschenkette
DE112012001522A5 (de) Kurbelwellenriemenscheibe
FR2980994B1 (fr) Prehenseur multi-plaquettes.
FI20115568L (fi) Vaijerilenkki
UA22489S (uk) Ланцюжок
FI20100154A (fi) Moottorisahan teräketju
FIU20110057U0 (fi) Koirankoppi
FIU20114100U0 (fi) Hirsi
EE01127U1 (et) Valgusti